Theralase Technologies Inc. (TLT.V)
- ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase® " or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation ...
- ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
- ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
